T. Rowe Price Investment Management
APLT

T. Rowe Price Investment Management’s Applied Therapeutics APLT Stock Holding History

T. Rowe Price Investment Management’s Portfolio APLT Stock Details APLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-21,747,844
Closed -$2.17M – 661
2025
Q4 		$2.17M Buy
21,747,844
+344,544
+2% +$219K ﹤0.01% 616
2025
Q3 		$12.8M Buy
21,403,300
+2,719,310
+15% +$1.28M 0.01% 543
2025
Q2 		$5.79M Buy
18,683,990
+8,303,400
+80% +$3.21M ﹤0.01% 577
2025
Q1 		$5.08M Buy
10,380,590
+4,959,670
+91% +$2.92M ﹤0.01% 587
2024
Q4 		$4.64M Buy
5,420,920
+5,213,370
+2,512% +$32.7M ﹤0.01% 578
2024
Q3 		$1.76M Buy
+207,550
New +$1.22M ﹤0.01% 589

T. Rowe Price Investment Management's APLT Position: Q1 2026 in Review

T. Rowe Price Investment Management sold out of Applied Therapeutics (APLT) in Q1 2026, closing a stake of 21,747,844 shares — an estimated $2.17M sold.

T. Rowe Price Investment Management first reported a position in APLT in Q3 2024 and held it in 6 quarters. The position peaked at $12.8M in Q3 2025. 0 funds tracked by Wall St. Rank hold APLT as of Q1 2026.

  • T. Rowe Price Investment Management reported no remaining Applied Therapeutics position as of Q1 2026 after selling out during the quarter.
  • T. Rowe Price Investment Management sold 21,747,844 Applied Therapeutics shares in Q1 2026, an estimated $2.17M.
  • T. Rowe Price Investment Management first reported a position in Applied Therapeutics in Q3 2024 and held it in 6 quarters.
  • T. Rowe Price Investment Management's Applied Therapeutics position peaked at $12.8M in Q3 2025.
  • 0 funds tracked by Wall St. Rank held Applied Therapeutics as of Q1 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q1 2026, filed 15 May 2026.